Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy

作者：Molassiotis Alex; Nguyen Allison Martin; Rittenberg Cynthia N; Makalinao Alex; Carides Alexandra^*

来源：Future Oncology, 2013, 9(10): 1443-1450.

DOI：10.2217/fon.13.155

• antiemetic
• nausea
• patient outcomes
• quality of life
• vomiting

Aim: This study aimed to determine how aprepitant affects the impact of chemotherapy-induced nausea and vomiting (CINV) on daily activities during highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). Patients %26 methods: Patients received aprepitant plus standard antiemetic therapy (ondansetron plus dexamethasone) or standard antiemetic therapy alone. Data were analyzed from pooled data of two Phase III randomized, double-blind HEC trials and one MEC trial. Patients completed the Functional Living Index-Emesis questionnaire. Results: A significantly greater percentage of patients receiving aprepitant reported no or minimal CINV impact on daily life (overall total Functional Living Index-Emesis score %26gt;6) compared with those receiving standard therapy alone (HEC: 74.4 vs 63.9%, respectively; p %26lt; 0.01; MEC: 73.4 vs 66.3%; p %26lt; 0.05). In HEC, favorable responses to aprepitant treatment persisted in nausea (70.2 vs 60.9%) and vomiting domains (84.6 vs 68.7%; both p %26lt; 0.01). Similar results were seen in MEC. Conclusion: Addition of aprepitant reduced CINV impact on daily life compared with standard antiemetic therapy.

• 出版日期2013-10